Brainstorm Cell Therapeutics Inc. BCLI
0.97
0.02
2.11%
as of 25 Sep
- Market cap
- $7.0M
- P/E
- 0.0×
Follow BCLI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.06 | 0.03 | 0.02 | 0.03 |
Net Debt/EBITDA |
(0.05) | (0.43) | (0.65) | (0.35) | |
Debt/Assets |
7.32% | 94.62% | 176.03% | 160.03% | |
Debt/Equity |
(0.01) | (0.10) | (0.12) | (0.11) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.52 | 0.30 | 0.62 | 0.23 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.10) | (0.08) | (0.12) | (0.08) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(0.70) | (1.08) | (1.00) | (1.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.70) | (1.08) | (1.00) | (1.05) | |
Free Cash Flow |
(1.10) | (0.74) | (1.32) | (0.89) | |
Working Capital |
(8.51) | (10.70) | (11.58) | (12.07) | |
Net Current Asset Value |
(8.56) | (10.70) | (11.58) | (12.07) | |
| Other line items | |||||
Quick Ratio |
0.01 | 0.01 | 0.01 | 0.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.08) | (0.12) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.06 | 0.07 | 0.09 | 0.13 | |
Average Payables |
5.56 | 6.20 | — | 6.05 | |
Average Assets |
1.70 | 1.43 | 2.16 | 1.68 | |
Average Common Equity |
(6.87) | (8.87) | (9.23) | (8.83) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates